Investors
Newsroom
Careers
- Job Openings

Areas of Focus
Our Medicines
Pipeline
Science & Innovation
Patients & Caregivers
About
- Leadership Team
- Corporate Governance

Investors
Newsroom
Careers
- Job Openings

Lab technicians examining samples

Lab technicians examining samples

Latest News and Events

Home /

Newsroom

Now Approved

FDA Approval of Plozasiran to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Filter by

Year Published
- 2025
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011

Selections

April 16, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Read More

April 15, 2021

Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

Read More

March 1, 2021

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Read More

February 4, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results

Read More

January 25, 2021

Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

Read More

January 19, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results

Read More

December 7, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Read More

November 30, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

Read More

November 25, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

Read More

November 23, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

Read More

1...19 20 21 22 23...58

Continue to Site

Footer Navigation

Areas of Focus
Pipeline
Science & Innovation
Patients & Caregivers
About
Careers

Facebook
Instagram
LinkedIn
Twitter

Privacy Policy
Cookie Policy
Terms of Use
Sitemap
Contact Us
Safety Reporting

© 2025 Arrowhead Pharmaceuticals, Inc.